Why Little Green Pharma Walked Away from WA Sale and Leaseback Deal
Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.
- Termination of sale and leaseback contract due to unresolved commercial terms
- Company retains ownership of South-West WA production facility
- No expected impact on business operations or production
- Deal originally announced in February 2026
- LGP remains a leading global medicinal cannabis supplier
Background to the Sale and Leaseback Plan
In February 2026, Little Green Pharma (ASX:LGP) announced a significant move to sell and lease back its production facility located in South-West Western Australia. This strategy is often used by companies to unlock capital tied up in property assets while continuing to operate from the same site. The deal was subject to a range of conditions precedent, including commercial agreements that needed to be finalised between the parties.
Why the Deal Fell Through
Just a month later, LGP confirmed the contract had been terminated because the parties could not reach agreement on certain key commercial terms. While the company did not disclose the specific sticking points, the termination clause was exercised in accordance with the contract’s terms. This outcome means LGP will continue to own and operate its production facility without the financial restructuring the sale and leaseback would have provided.
Implications for Little Green Pharma
Despite the termination, LGP reassured investors and stakeholders that the decision is not expected to impact its business operations or production capabilities. The company remains a vertically integrated medicinal cannabis producer with a strong presence across Australia and Europe, including three production sites and a diversified export footprint. Retaining ownership of the WA facility preserves operational control and asset value on the balance sheet.
Strategic Context and Market Position
Little Green Pharma is one of the top three medicinal cannabis suppliers in Australia and a leading exporter to key European markets such as France, Germany, and the UK. The company’s portfolio and distribution network position it well for growth amid expanding global demand. While the sale and leaseback could have provided additional liquidity or capital flexibility, the decision to retain the asset suggests management prioritises operational stability and long-term asset value.
Looking Ahead
Investors will be watching closely for any updates on LGP’s capital management strategy following this termination. The company’s ability to adapt to evolving regulatory environments and maintain a robust supply chain remains critical. Whether alternative asset monetisation initiatives or financing options will be pursued remains to be seen.
Bottom Line?
LGP’s decision to keep its WA production facility signals a cautious approach to capital management amid a dynamic medicinal cannabis market.
Questions in the middle?
- What were the specific commercial terms that could not be agreed upon?
- Will Little Green Pharma pursue alternative asset monetisation strategies?
- How might this decision affect LGP’s financial flexibility and growth plans?
